Rituximab Monoclonal Antibody Injection
Rituximab is a genetically engineered chimeric monoclonal antibody targeting CD20 on B-cells, used for treating non-Hodgkin lymphoma and rheumatoid arthritis. It falls under HTS 3002.15.00.11 as an immunological product containing monoclonal antibodies, put up in measured doses for retail sale in pre-filled syringes or vials.
Import Duty Rates by Country of Origin
Alternative Classifications
This product could be classified differently depending on its characteristics or intended use.
If containing blood sera or antisera rather than monoclonal antibodies
Products with polyclonal antisera like immunoglobulins fall under antisera subheading, not specific to monoclonal antibodies.
If not put up in measured doses or retail packings
Bulk immunological products without retail packaging classify under other forms, excluding measured doses.
If classified primarily as hormones rather than immunological products
Certain biotech hormones from heading 2937 take precedence over immunological classification per chapter notes.
Not sure which classification is right?
The Tariff Assistant works through the GRI rules on your specific product to reach the right HTS code — and can price the duty on it in the same conversation.
Import Tips & Compliance
• Obtain FDA biologics license and ensure proper cold chain documentation (2-8°C) to avoid spoilage during import
• Include certificates of analysis verifying monoclonal antibody purity and biotech origin; declare as immunological product
• Avoid misclassification as general pharmaceuticals; common pitfall is insufficient proof of measured doses for retail
Related Products under HTS 3002.15.00.11
Trastuzumab (Herceptin) Infusion Vial
Trastuzumab is a humanized monoclonal antibody against HER2 protein, used in HER2-positive breast cancer therapy. Classified under HTS 3002.15.00.11 for its immunological role in targeted cancer treatment, supplied in measured dose vials for retail pharmacy sale.
Infliximab (Remicade) Lyophilized Powder
Infliximab is a chimeric monoclonal antibody against TNF-alpha for psoriasis and ulcerative colitis. HTS 3002.15.00.11 applies to this biotech-derived immunological product in measured retail doses for reconstitution.
Pembrolizumab (Keytruda) Injection
Pembrolizumab targets PD-1 for advanced cancer immunotherapy like Hodgkin lymphoma. HTS 3002.15.00.11 covers this monoclonal antibody immunological product in pre-filled syringes for retail therapeutic use.
Cetuximab (Erbitux) Infusion Kit
Cetuximab is a chimeric monoclonal antibody against EGFR for colorectal cancer. Under HTS 3002.15.00.11 for retail-measured doses regulating tumor immunology.
Denosumab (Prolia) Prefilled Syringe
Denosumab is a human monoclonal antibody inhibiting RANKL for osteoporosis. HTS 3002.15.00.11 applies to this immunological product in retail syringes.
Ranibizumab (Lucentis) Intravitreal Injection
Ranibizumab is a humanized monoclonal antibody fragment for wet AMD. Classified HTS 3002.15.00.11 as immunological VEGF inhibitor in measured doses.